🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Netherlands
Clinical trial register · European Union · CTIS

Clinical Trials in Netherlands, 2026

The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show — this register states both numbers rather than picking one.

Download CSV
Source: EMA Clinical Trials Information System (CTIS). Showing the 2500 most recently authorised of 12479 total CTIS records — a stated recency window, not the full historical archive. Synced 24 Sep 2026, 03:17 UTC
2500
Shown in this register
most recently authorised
12,479
Total on CTIS
full historical archive
743
Phase III
within the shown window
Top member states
Spain 1015 France 884 Germany 862 Italy 739 Poland 582 Netherlands 531
Narrow the registerReset
Phase
Phase I 555 Phase I/II 212 Phase II 730 Phase III 743 Phase IV 260
Lead sponsor
AstraZeneca AB 63 Assistance Publique Hopitaux De Paris 49 Merck Sharp & Dohme LLC 48 Pfizer Inc. 44 Novo Nordisk A/S 43
Member state
Spain 1015 France 884 Germany 862 Italy 739 Poland 582 Netherlands 531 Belgium 431 Czechia 331
All 28 states

Trials with a site in Netherlands

531 of 2500 shown studies
Download
Phase
Study
Lead sponsor
Area
Member states
Decision
Phase II
A Phase 2, Randomized, Double-blinded, Placebo-controlled, Dose Range-finding, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ALXN2420, a Growth Hormone Receptor Antagonist, Administered Subcutaneously in Combination with Somatostatin Analogs in Adult Participants with Acromegaly
2025-521243-20-00Acromegaly
Alexion Pharmaceuticals Inc.
Hormonal diseases
Lithuania, Romania, Denmark, Italy, Hungary, Poland, Netherlands
29/09/2025
Phase II
Clinical Randomised Phase 2 Trial of AP31969 versus Placebo for Rhythm Control of Atrial Fibrillation.
2025-521377-14-00Atrial fibrillation
Acesion Pharma ApS
Cardiovascular Diseases
Hungary, Italy, Denmark, Bulgaria, Poland, Netherlands, Germany
29/09/2025
Phase II
A Phase 2b, Multicenter, Randomized, Double-blind, Parallel group, Placebo-controlled, Dose Range Finding Study to Evaluate the Efficacy, Safety, and Tolerability of Nebulized CSL787 in Adults (18 to 85 years) with Non-cystic Fibrosis Bronchiectasis
2024-518821-13-00Non-cystic Fibrosis Bronchiectasis
CSL Behring LLC
Respiratory Tract Diseases
Spain, Belgium, Germany, Greece, Denmark, Netherlands, Hungary, Italy, France, Poland
26/09/2025
Phase III
A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
2024-517131-52-00Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymp…
BeOne Medicines AG
Neoplasms
France, Sweden, Czechia, Austria, Belgium, Germany, Denmark, Spain, Netherlands, Italy, Ireland, Poland
26/09/2025
Phase III
EASi-PROTKT™ - A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease
2025-521188-11-00hypertension, cardiovascular disease, Type 2 diabetes
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Cardiovascular Diseases
Lithuania, Netherlands, Ireland, Romania, France, Hungary, Finland, Latvia, Austria, Germany, Greece, Italy, Sweden, Denmark, Czechia, Belgium, Slovakia, Croatia, Spain, Norway, Bulgaria, Poland, Portugal
24/09/2025
Phase II
A multicenter, randomized, double-blind, placebo-controlled, Phase II platform study to assess the efficacy and safety of investigational compound(s) in patients with moderate to severe atopic dermatitis
2024-519081-49-00Moderate to severe atopic dermatitis
Novartis Pharma AG
Skin and Connective Tissue Diseases
Czechia, Netherlands, Poland, Germany, Spain, Hungary, France, Italy, Slovakia
22/09/2025
Phase I
A Study to assess the Safety, Tolerability and effect of RO7673396 when used alone as well as with other cancer medications in participants with Advanced Solid Tumors
2024-519622-20-00Advanced Solid Tumors Harboring RAS Mutation(S)
F. Hoffmann-La Roche AG
Neoplasms
Germany, Netherlands, Spain, Denmark, France, Belgium
22/09/2025
Phase I
Research into new test methods to measure pain with two existing drugs (nefopam and oxycodone)
2025-522389-66-00(Chronic) pain
Centre for Human Drug Research
Nervous System Diseases
Netherlands
22/09/2025
Phase II
A Phase 2, Open-Label, Multicenter Study of Zoldonrasib(RMC-9805) in Previously Treated Patients with RAS G12DMutant Non-Small Cell Lung Cancer (NSCLC) – Subprotocol D
2025-521681-10-00Lung Cancer
Revolution Medicines Inc.
Respiratory Tract Diseases
Germany, Greece, Netherlands, Czechia, France, Austria, Denmark, Spain, Italy
22/09/2025
Phase I
An exploratory study to investigate the impact on the viral reservoir of adding a broadly neutralizing antibody with or without an attachment inhibitor to an integrase inhibitor-based antiretroviral therapy regimen in adults living with HIV (ENTRANCE)
2025-520629-19-00HIV Infections
Viiv Healthcare UK Limited
Virus Diseases
Netherlands, Spain, Belgium, Denmark
22/09/2025
Phase III
A Double-blind, Randomized,Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants with Elevated Lipoprotein(a)
2025-520554-11-00Cardiovascular Disease
Amgen Inc.
Cardiovascular Diseases
Spain, Hungary, Portugal, Greece, Germany, Italy, Austria, Ireland, Romania, Slovakia, Netherlands, Czechia, Bulgaria, Denmark, France, Poland, Belgium
22/09/2025
Phase II
STS-001: An explorative clinical study to assess the potential of intravenously administered sodium thiosulfate in subjects with primary Raynaud’s phenomenon
2023-509432-25-00Raynaud’s phenomenon
Universitair Medisch Centrum Groningen
Cardiovascular Diseases
Netherlands
18/09/2025
Phase II
A Phase II, randomized, open-label, multi-center study of JSB462 in combination with lutetium (177Lu) vipivotide tetraxetan in adult male patients with PSMA-positive metastatic castration resistant prostate cancer (mCRPC)
2024-520155-24-00Metastatic castration resistant prostate cancer (mCRPC)
Novartis Pharma AG
Neoplasms
Netherlands, Austria, Germany, Italy, France, Czechia, Spain
17/09/2025
Phase III
A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084, Cetuximab, and mFOLFOX6 versus mFOLFOX6 With or Without Bevacizumab as First-line Treatment of Participants With KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer (KANDLELIT-012).
2024-517232-22-00KRAS G12C-mutant, Locally Advanced Unresectable or Metastat…
Merck Sharp & Dohme LLC
Neoplasms
Poland, Spain, Netherlands, Italy, Finland, Romania, France, Germany, Hungary
17/09/2025
Phase I
A Study to Investigate the Effect of RO7504109 on Immune Cells in Healthy Participants
2025-522181-71-00Not Applicable (N/A)
F. Hoffmann-La Roche AG
Population Characteristics
Netherlands
16/09/2025
Phase III
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate Efficacy and Safety of Mezagitamab (TAK-079) in Study Participants with Primary IgA Nephropathy in Combination with Stable Background Therapy
2025-520825-19-00IgAN is Primary Immunoglobulin A Nephropathy (IgAN) (also k…
Takeda Development Center Americas Inc.
Immune System Diseases
Spain, Czechia, Austria, Hungary, Germany, Norway, Slovenia, France, Sweden, Netherlands, Poland, Italy
16/09/2025
Phase I/II
A Phase 1/2, Single-arm, Open-Label Trial to Evaluate the Safety and Efficacy of Nadofaragene Firadenovec Instilled to the Renal Pelvis in Adult Subjects with Low-Grade Upper Tract Urothelial Carcinoma (LG-UTUC)
2024-514360-70-00Low-grade upper track urothelial carcinoma (LG-UTUC)
Ferring Pharmaceuticals A/S
Female Urogenital Diseases and Pregnancy Complications
Spain, France, Netherlands
16/09/2025
Phase IV
A Single-arm, Open-label Phase 4 Study of Nirogacestat in Adult Premenopausal Females with Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
2024-515215-21-00DESMOID TUMOURS/AGGRESSIVE FIBROMATOSIS (DT/AF)
Springworks Therapeutics Inc.
Skin and Connective Tissue Diseases
Netherlands, Italy, Spain, Belgium, Germany
15/09/2025
Phase II
Intraperitoneal irinotecan combined with systemic therapy for patients with gastric peritoneal metastases: A phase II, multicenter study
2025-521468-36-00Gastric peritoneal metastases
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Neoplasms
Netherlands
15/09/2025
Phase III
A phase III trial of a De-escalated Immune-strategy During first-line treAtment in patients with metastatic non-small Cell lung cancer (NSCLC): DIDaC
2025-520792-67-00Patients with advanced, metastatic NSCLC that have not prog…
Leids Universitair Medisch Centrum (LUMC)
Neoplasms
Netherlands
12/09/2025
Phase I
A Phase 1/1b Study of IAM1363 in HER2 Cancers
2024-519188-17-00Relapsed/refractory malignancy with documented diagnosis of…
Iambic Therapeutics Inc.
Neoplasms
Spain, France, Ireland, Italy, Netherlands
11/09/2025
Phase IV
Early treatment of Atrial fibrillation for Stroke prevention Trial in acute STROKE (EAST-STROKE)
2025-521260-35-00acute ischemic stroke and atrial fibrillation (AF)
University Medical Center Hamburg-Eppendorf
Cardiovascular Diseases
Spain, Germany, Netherlands
11/09/2025
Phase I/II
A Randomized, Parallel, Open-Label, Phase 1/2a Study to Assess the Safety and Tolerability of Multiple Doses of the Bacteriophage Cocktail TP-122 (Component TP-122A), for the Treatment of Ventilator-Associated Pneumonia
2025-521533-85-00Ventilator-Associated Pneumonia
Technophage Investigacao E Desenvolvimento Em Biotecnologia S.A.
Bacterial Infections and Mycoses
Portugal, Netherlands
09/09/2025
Phase I
A study investigating the safety, absorption, and elimination of NT 0150, a new compound that may potentially be used in the treatment of brain disorders, like Alzheimer’s disease and Parkinson’s disease.
2024-520142-32-00Cryopyrin associated periodic syndrome
Nodthera Limited
Immune System Diseases
Netherlands
05/09/2025
Phase I
Nebulised lIposomal aMphotericin B in chronic pUlmonary aSpergillosis: a deposition study
2025-521770-34-00Chronic pulmonary aspergillosis
Radboud universitair medisch centrum Stichting
Bacterial Infections and Mycoses
Netherlands
04/09/2025
Phase I
A study investigating the safety, tolerability, pharmacokinetics (absorption, distribution, metabolism and elimination) and effect of single and multiple doses of MTX46943, a new compound that may potentially be used in the treatment of Alzheimer’s disease and other neurological disorders
2025-522368-34-00Alzheimer’s Disease
Muna Therapeutics ApS
Nervous System Diseases
Netherlands
04/09/2025
Phase III
The efficacy and safety of Intramuscular Methylprednisolone in patients with Hand OsteoArthritis: the IMHOA trial
2024-518344-20-00Hand osteoarthritis
Sint Maartenskliniek Stichting
Immune System Diseases
Netherlands
04/09/2025
Phase III
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Program to Evaluate the Efficacy and Safety of Tulisokibart in Participants with Moderately to Severely Active Crohn’s Disease
2024-518296-56-00Crohn’s Disease
Merck Sharp & Dohme LLC
Digestive System Diseases
Spain, Austria, Lithuania, France, Belgium, Germany, Sweden, Czechia, Finland, Croatia, Latvia, Portugal, Netherlands, Italy, Denmark, Slovakia, Romania, Poland, Ireland, Hungary, Greece
03/09/2025
Phase I
Multiple Ascending Dose Study of LY4256984 in Participants with Sporadic Amyotrophic Lateral Sclerosis
2025-521295-60-00Sporadic Amyotrophic Lateral Sclerosis
Eli Lilly & Co.
Nervous System Diseases
Belgium, Spain, Netherlands, Germany
02/09/2025
Phase III
A Randomized, Open-Label, Controlled Phase 3 Study Comparing Daratumumab, Lenalidomide and Dexamethasone Induction followed by Linvoseltamab Versus continued Daratumumab, Lenalidomide, and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma Patients
2024-519827-16-00Newly Diagnosed Transplant Ineligible Multiple Myeloma Pati…
European Myeloma Network B.V., Emn Trial Office S.r.l. Impresa Sociale
Neoplasms
Norway, Denmark, Spain, Sweden, Austria, Netherlands, Greece, Germany, Italy, Belgium, Portugal, Estonia, Croatia, Ireland, Czechia, Finland
01/09/2025
Phase III
A Phase 3, Open Label, Multicenter, Randomized Study of First Line Tarlatamab in combination with Durvalumab, Carboplatin and Etoposide versus Durvalumab, Carboplatin and Etoposide in Untreated Extensive Stage Small-Cell Lung Cancer (DeLLphi-312)
2024-520050-38-00Extensive stage small cell lung cancer (ES-SCLC). …
Amgen Inc.
Neoplasms
Portugal, Germany, Spain, Italy, Denmark, Netherlands, France, Austria, Greece, Belgium, Hungary, Poland, Romania
01/09/2025
Rows per page Showing 501–531 of 531
Previous 4 5 6
Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS), filtered. Derived from the EMA Clinical Trials Information System. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-europe/country/netherlands?page=6

Query this register directly
GET /api/export.php?register=trials-eu&format=json Try it now →

About this register

This register is built from the EU Clinical Trials Information System (CTIS), run by the European Medicines Agency: the single register for every trial authorised under the EU Clinical Trials Regulation (536/2014). CTIS held 12,479 trial records at the last sync on 24 Sep 2026, 03:17 UTC; this register shows the 2,500 most recently authorised of them, a stated recency window rather than the full archive. The list can be downloaded as CSV or JSON.

This page shows the 531 of those trials with a site in Netherlands.

How many recently authorised EU trials have a site in Netherlands?

531 of the 2,500 most recently authorised trials in this register list a site in Netherlands; 229 of them are Phase III. Trials are counted by authorisation on CTIS, not by recruitment status, which CTIS does not publish in the same form as ClinicalTrials.gov.

Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See the Ireland, UK or USA registers. For approved medicines, see the EMA Approvals Tracker.